Detalhe da pesquisa
1.
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Blood
; 140(9): 980-991, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35687757
2.
Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study.
Eur J Haematol
; 110(3): 280-288, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36403132
3.
Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.
Am J Hematol
; 98(8): 1246-1253, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246953
4.
Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study.
Ann Hematol
; 101(10): 2169-2177, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35999387
5.
Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL study.
Ann Hematol
; 103(5): 1803, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38519606
6.
Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trial.
Br J Haematol
; 198(4): e59-e62, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35655238
7.
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results.
Haematologica
; 107(7): 1698-1702, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35172561
8.
Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up.
Blood Adv
; 7(19): 5890-5897, 2023 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37459203
9.
Effect of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intravenous Rivipansel.
Clin Pharmacol Drug Dev
; 9(8): 918-928, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32579796
10.
Improvement of pancytopenia and thrombocytopenia with decreasing mosaicism for isochromosome Xp.
Pediatr Blood Cancer
; 52(5): 650-2, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19145639
11.
Lack of Effect of Rivipansel on QTc Interval in Healthy Adult African American Male Subjects.
J Clin Pharmacol
; 57(10): 1315-1321, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28510346
12.
Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities.
Blood Coagul Fibrinolysis
; 26(8): 912-8, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26196195
13.
Assessment of relative bioavailability of two presentations of moroctocog alfa (AF-CC) in subjects with moderately severe or severe hemophilia A.
Clin Pharmacol Drug Dev
; 4(3): 237-41, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-27140804
14.
Factors that influence the bleeding phenotype in severe hemophilic patients.
Blood Coagul Fibrinolysis
; 24(7): 683-90, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24056291
15.
Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children.
J Pediatr
; 148(4): 489-94, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16647411